Literature DB >> 8748665

The yohimbine-induced anticonflict effect in the rat, Part I. Involvement of noradrenergic, serotonergic and endozepinergic(?) mechanisms.

A Söderpalm1, O Blomqvist, B Söderpalm.   

Abstract

The alpha 2-adrenoceptor antagonist yohimbine has in several previous studies been found to produce anticonflict effects comparable to those produced by the benzodiazepines (BDZ) in rat punished conflict models. In this and a following paper we have tried to elucidate the neurochemical mechanisms underlying these effects in a modified Vogel's drinking conflict test. Since yohimbine previously has been demonstrated to interfere both with noradrenaline (NA) and serotonin (5-HT) neurochemistry, and, in addition, shows affinity for the BDZ binding site, we have focused on the putative involvement of these neuronal systems in the yohimbine-induced anticonflict effect. The alpha 2-adrenoceptor agonist clonidine (10 micrograms/kg, i.p.) completely antagonized the anticonflict effect of yohimbine (4.0 mg/kg, i.p.), whereas the alpha 1-adrenoceptor agonist ST 587 (1.0 mg/kg, i.p.) had no effect. The anticonflict effect of yohimbine was totally abolished also following lesioning of NA neurons with 6-hydroxy-dopamine. A high dose of the mixed beta 1 and beta 2 adrenoceptor antagonist propranolol (8.0 mg/kg, i.p.) caused a partial blockade of the yohimbine-induced effect in intact animals, whereas the selective beta 1-adrenoceptor antagonist metoprolol (4.0 mg/kg, i.p.) had no significant effect and the alpha 1-adrenoceptor antagonist prazosin instead potentiated the anticonflict action. The anticonflict effect of yohimbine was dose-dependently antagonized also by the 5-HT precursor L-5-hydroxytryptophan (25-100 mg/kg, i.p.). The BDZ receptor antagonist flumazenil (10 mg/kg, p.o.), as well as Ro 15-4513 (1.0 mg/kg, p.o.), a partial inverse agonist at BDZ receptors, partly, but significantly, counteracted the yohimbine-induced anticonflict effect, whereas low doses of both the chloride channel blocker picrotoxin and the GABAA antagonist bicuculline only tended to counteract the yohimbine effect. Taken together, the results in the present behavioral paper indicate that the anticonflict effect of yohimbine involves both increased NA and decreased 5-HT activity, and that direct or indirect activation of BDZ receptors may also be involved. Neurochemical findings related to these behavioral results are presented in a following paper.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8748665     DOI: 10.1007/bf01276457

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  49 in total

1.  Alpha 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat.

Authors:  A J Gower; M D Tricklebank
Journal:  Eur J Pharmacol       Date:  1988-10-11       Impact factor: 4.432

2.  Biphasic effects of clonidine on conflict behavior: involvement of different alpha-adrenoceptors.

Authors:  B Söderpalm; J A Engel
Journal:  Pharmacol Biochem Behav       Date:  1988-06       Impact factor: 3.533

3.  Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models.

Authors:  M Heilig; B Söderpalm; J A Engel; E Widerlöv
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Catecholamine receptors on locus coeruleus neurons: pharmacological characterization.

Authors:  J M Cedarbaum; G K Aghajanian
Journal:  Eur J Pharmacol       Date:  1977-08-15       Impact factor: 4.432

5.  The yohimbine-induced anticonflict effect in the rat, Part II. Neurochemical findings.

Authors:  A Söderpalm; F Ehrenström; B Söderpalm
Journal:  J Neural Transm Gen Sect       Date:  1995

6.  Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm.

Authors:  M Davis; D E Redmond; J M Baraban
Journal:  Psychopharmacology (Berl)       Date:  1979-10       Impact factor: 4.530

Review 7.  Pharmacological and clinical effects of buspirone.

Authors:  D P Taylor; M S Eison; L A Riblet; C P Vandermaelen
Journal:  Pharmacol Biochem Behav       Date:  1985-10       Impact factor: 3.533

8.  GABAergic Interneurons are the Major Postsynaptic Targets of Median Raphe Afferents in the Rat Dentate Gyrus.

Authors:  K. Halasy; R. Miettinen; E. Szabat; T. F. Freund
Journal:  Eur J Neurosci       Date:  1992       Impact factor: 3.386

9.  Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT).

Authors:  J A Engel; S Hjorth; K Svensson; A Carlsson; S Liljequist
Journal:  Eur J Pharmacol       Date:  1984-10-15       Impact factor: 4.432

10.  A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants.

Authors:  S E File; J R Hyde
Journal:  Pharmacol Biochem Behav       Date:  1979-07       Impact factor: 3.533

View more
  5 in total

1.  A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test.

Authors:  L Mathiasen; N R Mirza
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

2.  The yohimbine-induced anticonflict effect in the rat, Part II. Neurochemical findings.

Authors:  A Söderpalm; F Ehrenström; B Söderpalm
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals.

Authors:  Mark K Greenwald; Leslie H Lundahl; Caren L Steinmiller
Journal:  Psychopharmacology (Berl)       Date:  2012-11-17       Impact factor: 4.530

Review 4.  The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking.

Authors:  Sunila G Nair; Tristan Adams-Deutsch; David H Epstein; Yavin Shaham
Journal:  Prog Neurobiol       Date:  2009-06-02       Impact factor: 11.685

Review 5.  Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework.

Authors:  Mark K Greenwald
Journal:  Neurobiol Stress       Date:  2018-08-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.